Thromb Haemost 1996; 75(06): 908-914
DOI: 10.1055/s-0038-1650393
Original Article
Schattauer GmbH Stuttgart

A Sensitive Bioimmunoassay for Thrombin-cleaved Two-chain Urokinase-type Plasminogen Activator in Human Body Fluids

Ellen A M Braat
The Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Ume Nauland
The Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Gerard Dooijewaard
The Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Dingeman C Rijken
The Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 06 November 1995

Accepted after resubmission 02 February 1996

Publication Date:
11 July 2018 (online)

Summary

Thrombin cleaves single-chain urokinase-type plasminogen activator (scu-PA) into a two-chain form (tcu-PA/T), which is virtually inactive in plasminogen activator assays. Little is known about the physiological importance of tcu-PA/T. To examine the occurrence of tcu-PA/T in vivo, we developed a sensitive and specific bioimmunoassay (BIA) for the assessment of tcu-PA/T in human body fluids. In this BIA, urokinase antigen was immuno-immobilized in microtiter plates and treated with cathepsin C, a specific activator of tcu-PA/T, after which plasminogen activator activity was measured. The occurrence of tcu-PA/T was examined in the plasma of 27 healthy individuals and of 17 sepsis patients, and in the synovial fluid of 16 rheumatoid arthritis patients. In addition, the concentration of urokinase antigen and scu-PA were measured in all three groups. In the plasma of the healthy individuals no measurable amounts of tcu-PA/T could be found (< detection limit of 0.2 ng/ml). In the plasma of almost all sepsis patients tcu-PA/T could be detected (median value 0.4 ng/ml). The amount of tcu-PA/T was 12% of the amount of scu-PA and accounted for about 9% of urokinase antigen. In the synovial fluid of all rheumatoid arthritis patients tcu-PA/T could be measured (median value 5.4 ng/ml) at a concentration which was twofold higher than the concentration found for scu-PA. In this group tcu-PA/T contributed to about 47% of the urokinase antigen. From these data we conclude that inactivation of scu-PA by thrombin can take place in vivo under pathological conditions which involve the production of large amounts of thrombin. This way thrombin may regulate fibrinolysis and extracellular proteolysis. The BIA for tcu-PA/T can be of use for further research on the physiological role of tcu-PA/T.

 
  • References

  • 1 Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). J Clin Invest 1984; 73: 1731-1739
  • 2 Ellis V, Scully MF, Kakkar VV. Plasminogen activation by single-chain urokinase in functional isolation. J Biol Chem 1987; 262: 14998-15003
  • 3 Pannell R, Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase - a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69: 22-26
  • 4 Petersen LC, Lund LR, Nielsen LS, Danø K, Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988; 263: 11189-11195
  • 5 Lijnen HR, Van Hoef B, De Cock F, Collen D. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. Blood 1989; 73: 1864-1872
  • 6 Husain SS. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. Biochemistry 1991; 30: 5797-5805
  • 7 Liu J, Gurewich V. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 1991; 88: 2012-2017
  • 8 Liu J, Gurewich V. Fragment E-2 from fibrin substantially enhances prourokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry 1992; 31: 6311-6317
  • 9 Eaton DL, Scott RW, Baker JB. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem 1984; 259: 6241-6247
  • 10 Kasai S, Arimura H, Nishida M, Suyama T. Proteolytic cleavage of singlechain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260: 12377-12381
  • 11 Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-3489
  • 12 Marcotte PA, Henkin J. Characterization of the activation of pro-urokinase by thermolysi. Biochim Biophys Acta 1993; 1160: 105-112
  • 13 Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem 1994; 269: 9416-9419
  • 14 Schmitt M, Janicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992; 6 Suppl (Suppl. 04) 03-26
  • 15 De Munk GAW, Groeneveld E, Rijken DC. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (prourokinase) by thrombomodulin. J Clin Invest 1991; 88: 1680-1684
  • 16 Molinari A, Giorgetti C, Lansen J, Vaghi F, Orsini G, Faioni EM, Mannucci PM. Thrombomodulin is a cofactor for thrombin degradation of recombinant single-chain urokinase plasminogen activator “in vitro” and in a perfused rabbit heart model. Thromb Haemost 1992; 67: 226-232
  • 17 Liu J, Gurewich V. The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator. Blood 1993; 81: 980-987
  • 18 Collen D, Dewerchin M, Stassen JM, Kiekens L, Lijnen HR. Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin. Fibrinolysis 1989; 3: 197-202
  • 19 Abercrombie DM, Buchinski B, Salvato KA, Vovis GF, Stump DC, Broze RJ. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin. Thromb Haemost 1990; 64: 426-432
  • 20 Gurewich V, Pannell R. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. Blood 1987; 69: 769-772
  • 21 Rijken DC, De Munk GAW, Nauland U. Inactivation of single-chain urokinase-type plasminogen activator (pro-urokinase) by thrombin. Biol Clin Hematol 1993; 15: 127-131
  • 22 Dooijewaard G, Van Iersel JJL, Brommer EJP. Quantitation of pro-UK, UK and UK.inhibitor levels in plasma of patients and healthy men. In: Fibrinolysis (8th International Congress on Fibrinolysis) Binder BR. ed Churchill Livingstone; Edinburgh: 1986. Abstr 142
  • 23 Kluft C, Wijngaards G, Jie AFH. Intrinsic plasma fibrinolysis: involvement of urokinase-related activity in the factor XII-independent plasminogen proactivator pathway. J Lab Clin Med 1984; 103: 408-419
  • 24 Binnema DJ, Dooijewaard G, Turion PNC. An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein. Thromb Haemost 1991; 65: 144-148
  • 25 Binnema DJ, Van Iersel JJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986; 43: 569-577
  • 26 Mahmoud M, Gaffney PJ. Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA/INH). Thromb Haemost 1985; 53: 356-359
  • 27 Exner T, Koutts J. Simple immunochromometric assay for protein C activity. J Lab Clin Med 1986; 107: 405-411
  • 28 Lijnen HR, Van Hoef B, Collen D. Activation with plasmin of two-chain urokinase-type plasminogen activator derived from single-chain urokinasetype plasminogen activator by treatment with thrombin. Eur J Biochem 1987; 169: 359-364
  • 29 Nauland U, Rijken DC. Activation of thrombin-inactivated single-chain urokinase-type plasminogen activator by dipeptidyl peptidase I (cathepsin C). Eur J Biochem 1994; 223: 497-501
  • 30 Kebabian PR, Henkin J. A chromogenic enzymatic assay capable of detecting prourokinase-like material in plasma. Thromb Res 1992; 65: 401-407
  • 31 Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1097
  • 32 Hoek JA, Sturk A, ten Cate JW, Lamping RJ, Berends F, Bom JJJ. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem 1988; 34: 2058-2062
  • 33 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombinantithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106
  • 34 Pelzer H, Stuber W. Markers of hemostatic activation: new perspectives using immunochemical methods for determination of prothrombin fragment Fl+2 and thrombin-antithrombin III complex. Thromb Haemost 1989; 62: 165 (Abstr. 494)
  • 35 Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987; 80: 1535-1544
  • 36 Wilhelm S, Wilhelm O, Schmitt M, Graeff H. Inactivation of receptor-bound pro-urokinase-type plasminogen activator (pro-uPA) by thrombin and thrombin/thrombomodulin complex. Biol Chem Hoppe-Seyler 1994; 375: 603-608
  • 37 Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Ann Rev Med 1987; 38: 417-32
  • 38 Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack E, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526
  • 39 Philippe J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 1991; 65: 291-295
  • 40 Philippe J, Dooijewaard G, Offner F, Turion P, Baele G, Leroux-Roels G. Granulocyte elastase, tumor necrosis factor-a and urokinase levels as prognostic markers in severe infection. Thromb Haemost 1992; 68: 19-23
  • 41 Jespersen J, Brommer EJP, Haverkate F, Nieuwenhuizen W. Degradation products of fibrin and of fibrinogen in synovial fluid and in plasma of patients with rheumatoid arthritis. Fibrinolysis 1989; 3: 183-186
  • 42 Carmassi F, De Negri F, Morale M, Puccetti R, Song KY, Chung SI. Assessment of coagulation and fibrinolysis in synovial fluid of rheumatoid arthritis patients. Fibrinolysis 1994; 8: 162-171
  • 43 Boffa MC, Burke B, Haudenschild CC. Preservation of thrombomodulin antigen on vascular and extravascular surfaces. J Histochem Cytochem 1987; 35: 1267-1276
  • 44 McCachren SS, Diggs J, Weinberg JB, Dittman WA. Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood 1991; 78: 3128-3132
  • 45 Brommer EJP, Dooijewaard G, Dijkmans BAC, Breedveld FC. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemost 1992; 68: 180-184
  • 46 Dorr PJ, Brommer EJP, Dooijewaard G, Vemer HM. Peritoneal fluid and plasma fibrinolytic activity in women with pelvic inflammatory disease. Thromb Haemost 1992; 68: 102-105
  • 47 Schwartz BS. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism. J Biol Chem 1994; 269: 8319-8323
  • 48 Manchanda N, Schwartz BS. Interaction of single-chain urokinase and plasminogen activator inhibitor type 1. J Biol Chem 1995; 270: 20032-20035
  • 49 Schmitt M, Kanayama N, Henschen A, Hollrieder A, Hafter R, Gulba D, Janicke F, Graeff H. Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA). FEBS Letters 1989; 255: 83-88